- Home
- HFRO vs FBRX Comparison
HFRO vs FBRX Comparison
Compare HFRO & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFRO | FBRX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.4M | 367.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HFRO | FBRX |
|---|---|---|
| Price | $6.35 | $33.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 179.8K | ★ 216.6K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.24 | $4.90 |
| 52 Week High | $6.45 | $34.19 |
Technical Indicators
Market Signals| Indicator | HFRO | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 67.88 |
| Support Level | $5.81 | $23.11 |
| Resistance Level | $6.06 | $34.19 |
| Average True Range (ATR) | 0.12 | 3.53 |
| MACD | 0.04 | 0.50 |
| Stochastic Oscillator | 88.14 | 90.22 |
Price Performance
Historical ComparisonAbout HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).